Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA) Q4 2024 Earnings Conference Call March 10, 2025 4:30 PM ET
Company Participants
John Fraunces – Director, Corporate Communications, LifeSci Advisors, IR
Jayson Rieger – President and CEO
John Kirby – Interim CFO
Conference Call Participants
Stacy Ku – TD Cowen
Gregory Renza – RBC Capital Markets
Kemp Dolliver – Brookline Capital Markets
Operator
Good evening, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals’ Fourth Quarter and Full Year 2024 Corporate Update Conference Call. At this time, all participants are in a listen-only mode. After the speaker’s remarks, there will be a question-and-answer session. As a reminder, this conference is being recorded.
I would now like to turn the call over to your host, John Fraunces of LifeSci Advisors. You may begin your conference.
John Fraunces
Thank you, operator. Hello, everyone, and welcome to Verrica Pharmaceuticals’ fourth quarter and full year 2024 corporate update conference call. With me on the line this evening are Jayson Rieger, President and Chief Executive Officer of Verrica Pharmaceuticals; John Kirby, Interim Chief Financial Officer; David Zawitz, Chief Operating Officer; Chris Hayes, Verrica’s Chief Legal Officer, and Aaron Hullitt, Chief of Commercial.
As a reminder, during today’s call, management will make forward-looking statements. These statements may include expectations related to the commercialization of wide can, the treatment of molluscum contagiosum in the United States, regulatory developments, the development of Verrica’s product candidates, company’s expected cash runway and its ability to obtain funding for future operations, and Verrica’s overall business strategy and planned operations.
These forward-looking statements are based on the company’s current expectations and involve inherent risks and uncertainties. And based on those risks and uncertainties, Verrica’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements. Please see Verrica’s SEC filings for important risk factors. Verrica
Read the full article here
